Loading patent…
AssigneesInstitut National de la Sante et de la Recherche Medicale, Université Paris Cité, Fondation Imagine, Assistance Publique-HôPitaux De Paris (Aphp), Universidad De Granada
InventorsLaurence LEGEAI-MALLET, Antonio SEGURA CARRETERO, Maria De La Luz CADIZ GURREA
Estimating the term…
FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin from T. cacao and showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3Y367C/+ femurs comparing to Fgfr3+/+ femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.
A method of treating a FGFR3-related chondrodysplasia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially pure (−)-epicatechin in a pharmaceutical composition that does not comprise flavonols, sweroside, hexenyl 5 xylopyranosyl glucopyranoside, procyanidin, catechin, cinchonain, or quercetin.
(canceled)
A method of treating a FGFR3-related chondrodysplasia in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a substantially pure (−)-epicatechin in a pharmaceutical composition that does not comprise flavonols, sweroside, hexenyl 5 xylopyranosyl glucopyranoside, procyanidin, catechin, cinchonain, quercetin obtained from a Theobroma cacao extract.
Dependencies are inferred from the claim text.